ACURIAN CASE STUDY:

Predictable, reliable, and measureable results



Acurian Doubles Enrollment Rates of US Sites to Rescue a Global Diabetes Study

This was a critical phase III trial designed to be the most important study in this sponsor's upcoming FDA submission for an innovative new Type 2 diabetes treatment.

The Enrollment Challenge

US Diabetes Market:

- Fierce competition among existing trials for patients.
- Lack of patient urgency to participate, since most are well controlled.
- Certain patient segments in which T2D is most prevalent are less likely to enroll in clinical studies.

Protocol:

- Acurian predicted and validated that 94% of interested diabetics would not qualify during prescreening due to highly restrictive I/E criteria.
- Participants faced difficult study requirements (additional injections, frequent finger sticks, and long study duration).

The Enrollment Scenario

- **Study start:** As part of a global study, the sponsor selected 70 diabetes specialty sites in the US anticipating completion of enrollment in 4.5 months.
- Month 2: The enrollment rate was much lower than anticipated, and the clinical trial team realized that without support, timelines were in significant jeopardy.
- Month 3: Acurian was hired to provide enrollment support for two months, then was asked to continue its efforts for another two months.
- Month 8: Enrollment concluded, accelerated by several months via Acurian, compared to how sites alone were on track to deliver.

How We Did It

Acurian quickly designed and launched a full-service recruitment campaign. Diabetes is Acurian's number one specialty, having supported over 4,200 diabetes sites and delivered over 5,000 randomized patients to diabetes sites worldwide. We used:

- Direct mail targeted to potential patients within Acurian's proprietary database of 100+ million people with self-reported health related conditions and who have opted-in to be contacted for clinical trials (including over 10 million diabetes sufferers)
- eRecruitment tactics (social media, online health networks, search, etc.)
- Print ads in select markets

Lessons Learned

Even the most capable sites were receptive to Acurian's recruitment support*.


- 81.3% of respondents rated Acurian's support as "helpful" or "extremely helpful."
- 93.8% would request Acurian support again if the sponsor launched another study.
- 82% would prefer the option to receive recruitment support upon site initiation, rather than wait one or more months after enrollment to receive support.

* Based on a post-project survey among sites

Campaign Results

The clinical trial team's decision to support US sites with centralized recruitment was an excellent one. Acurian exceeded its commitment (105% of goal) and delivered 120 randomized patients within budget, providing an excellent return on investment.


- Acurian increased sites' enrollment rates by 94%.
- Acurian contributed 48% of all patients enrolled in the US.
- Enrollment was completed 113% faster compared to how sites alone were on track to deliver*.



The Cost Efficiency of Acurian

Acurian cost \$2.7 million *less* than adding 125 sites (for a total of 195) which would have been required to reach the same enrollment volume in the same period of time.*

* IMS CRO CostPro® analysis, based on US site productivity





WHEN YOU CAN'T AFFORD A DELAY IN PATIENT ENROLLMENT

Acurian, Inc. is the leading full-service provider of global patient enrollment and retention solutions for the life sciences industry. For the past 20 years, our unique patient-first approach has provided sponsors with enrollment certainty by delivering the patients they need, when and where they need them.

www.acurian.com enrollment.certainty@acurian.com 223420144 United States Horsham, Pennsylvania 215.323.9000

Europe Cambridge, United Kingdom +44 1223 374799